Italy's demographic profile is stark: 24.1% of its population is aged ≥65 — the EU's highest — yet healthy life years trail total life expectancy by roughly 16 years (women: 85.4 vs. 69.6; men: 81.4 vs. 68.5). Multimorbidity and disability afflict more than 60% of adults over 75, with women carrying disproportionate burden as both patients and unpaid caregivers. The paper proposes integrating longevity medicine — encompassing multi-omic biomarkers, digital monitoring, Bayesian adaptive trials, and AI-driven risk stratification — into Italy's fragmented, prevention-underfunded National Health Service.
This is a position paper from a longevity advocacy foundation, not an interventional trial, so its proposals carry inherent institutional bias and lack empirical validation. That said, the lifespan-healthspan gap it documents is real, well-established in European health data, and worsening across most high-income nations. The five investment priorities identified — validated biological age biomarkers, interoperable digital platforms, adaptive trial infrastructure, explainable-AI stratification, and longevity-informed medical curricula — align with emerging consensus in geroscience, though the paper honestly acknowledges most tools remain at exploratory or surrogate stages with unproven clinical utility. The most consequential insight here is systemic: reactive, disease-coded healthcare architectures are structurally incapable of compressing morbidity. Incremental in framing, but the demographic urgency is genuine, and the roadmap, if rigorously evaluated for cost-effectiveness, is directionally sound.
